|
Antimicrobial
|
No. isolates (%)
|
*NARMS Report n(%)
|
P-value
|
|---|
|
Resistant
|
Intermediate
|
Susceptible
|
|---|
|
β-Lactams
|
|
Ceftriaxone
|
24 (16.3)
|
0 (0.0)
|
123 (83.7)
|
14 (5.3)
|
P < 0.05
|
|
Cefoxitin
|
9 (6.1)
|
0 (0.0)
|
138 (93.8)
|
14 (5.3)
|
P < 0.05
|
|
Ampicillin
|
132 (89.8)
|
0 (0.0)
|
15 (10.2)
|
52 (19.8)
|
P < 0.05
|
|
Amoxicillin/clavulanic acid, 2:1 ratio
|
97 (66.0)
|
0 (0.0)
|
50 (34.0)
|
14 (5.3)
|
P < 0.05
|
|
Quinolones
|
|
Ciprofloxacin
|
43 (29.2)
|
0 (0.0)
|
104 (70.7)
|
1 (0.4)
|
P < 0.05
|
|
Nalidixic acid
|
115 (78.2)
|
0 (0.0)
|
32 (21.8)
|
7 (2.7)
|
P < 0.05
|
|
Macrolides
|
|
Azithromycin
|
15 (10.2)
|
0 (0.0)
|
132 (89.8)
|
1 (0.4)
|
P < 0.05
|
|
Tetracyclines
|
|
Tetracycline
|
132 (89.8)
|
0 (0.0)
|
15 (10.2)
|
59 (22.5)
|
P < 0.05
|
|
Amphenicols
|
|
Chloramphenicol
|
113 (76.9)
|
2 (1.4)
|
32 (21.7)
|
42 (16.0)
|
P < 0.05
|
|
Sulfonamides and synergistic agents
|
|
Trimethoprim/sulfamethoxazole
|
114 (77.6)
|
0 (0.0)
|
33 (22.4)
|
6 (2.3)
|
P < 0.05
|
|
Sulfisoxazole
|
132 (89.8)
|
0 (0.0)
|
15 (10.2)
|
66 (25.2)
|
P < 0.05
|
|
Aminoglycosides
|
|
Gentamicin
|
102 (69.3)
|
1 (0.7)
|
44 (30.0)
|
8(3.1)
|
P < 0.05
|
|
Streptomycin
|
101 (68.7)
|
25 (17.0)
|
21 (14.3)
|
65 (24.8)
|
P < 0.05
|
- * The antimicrobial resistant number and rate of 262 S. Typhimurium isolates were cited from the National Antimicrobial Resistance Monitoring System report from the USA in 2014 [27]
